Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies

Background:Tumour heterogeneity is documented for many characters, including the production of growth factors, one of the hallmarks of cancer. What maintains heterogeneity remains an open question that has implications for diagnosis and treatment, as drugs that target growth factors are susceptible to the evolution of resistance.Methods:I use evolutionary game theory to model collective interactions between cancer cells, to analyse the dynamics of the production of growth factors and the effect of therapies that reduce their amount.Results:Five types of dynamics are possible, including the coexistence of producer and non-producer cells, depending on the production cost of the growth factor, on its diffusion range and on the degree of synergy of the benefit it confers to the cells. Perturbations of the equilibrium mimicking therapies that target growth factors are effective in reducing the amount of growth factor in the long term only if the reduction is extremely efficient and immediate.Conclusion:Collective interactions within the tumour can maintain heterogeneity for the production of growth factors and explain why therapies like anti-angiogenic drugs and RNA interference that reduce the amount of available growth factors are effective in the short term but often lead to relapse. Alternative strategies for evolutionarily stable treatments are discussed.

[1]  A. Deutsch,et al.  Studying the emergence of invasiveness in tumours using game theory , 2008, 0810.4724.

[2]  Marco Archetti,et al.  The volunteer's dilemma and the optimal size of a social group. , 2009, Journal of theoretical biology.

[3]  Robert J. Gillies,et al.  A microenvironmental model of carcinogenesis , 2008, Nature Reviews Cancer.

[4]  J. Nagy Competition and natural selection in a mathematical model of cancer , 2004, Bulletin of mathematical biology.

[5]  L. A. BACHa,et al.  Spatial Evolutionary Games of Interaction among Generic Cancer Cells , 2003 .

[6]  István Scheuring,et al.  COEXISTENCE OF COOPERATION AND DEFECTION IN PUBLIC GOODS GAMES , 2011, Evolution; international journal of organic evolution.

[7]  Niko Beerenwinkel,et al.  Evolutionary Games with Affine Fitness Functions: Applications to Cancer , 2011, Dyn. Games Appl..

[8]  J. Folkman,et al.  Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. , 2001, Journal of the National Cancer Institute.

[9]  G. Phillips Interpolation and Approximation by Polynomials , 2003 .

[10]  F. C. Santos,et al.  Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells , 2009, British Journal of Cancer.

[11]  Y. Iwasa,et al.  Evolutionary Dynamics of Intratumor Heterogeneity , 2011, PloS one.

[12]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[13]  I. Tomlinson,et al.  Game-theory models of interactions between tumour cells. , 1997, European journal of cancer.

[14]  Jacob G. Scott,et al.  Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game , 2011, British Journal of Cancer.

[15]  J. Pepper,et al.  Drugs that target pathogen public goods are robust against evolved drug resistance , 2012, Evolutionary applications.

[16]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[17]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[18]  P. W. Hemker,et al.  H. The Kinetics of Enzyme Cascade Systems General kinetics of enzyme cascades , 1969, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[19]  J. Ricard,et al.  Catalytic efficiency, kinetic co-operativity of oligomeric enzymes and evolution. , 1986, Journal of theoretical biology.

[20]  P Mendes,et al.  Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. , 1997, Trends in biochemical sciences.

[21]  Robert H. Austin,et al.  An analogy between the evolution of drug resistance in bacterial communities and malignant tissues , 2011, Nature Reviews Cancer.

[22]  Attila Szolnoki,et al.  Evolutionary dynamics of group interactions on structured populations: a review , 2013, Journal of The Royal Society Interface.

[23]  M. Archetti,et al.  Survival of the steepest: hypersensitivity to mutations as an adaptation to soft selection , 2009, Journal of evolutionary biology.

[24]  Andreas Deutsch,et al.  A Game Theoretical Perspective on the Somatic Evolution of cancer , 2008, 0810.4738.

[25]  J. Thiery,et al.  A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Kyle Summers,et al.  Evolutionary biology of cancer. , 2005, Trends in ecology & evolution.

[27]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[28]  A. Deutsch,et al.  Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion , 2008, Cell proliferation.

[29]  R. Solé,et al.  Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Archetti,et al.  Review: Game theory of public goods in one-shot social dilemmas without assortment. , 2012, Journal of theoretical biology.

[31]  R. Nesse,et al.  Evolutionary foundations for cancer biology , 2013, Evolutionary applications.

[32]  W. F. Bodmer,et al.  Modelling the consequences of interactions between tumour cells. , 1997, British Journal of Cancer.

[33]  L. Leibovici,et al.  The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review , 2013, PloS one.

[34]  D. Dexter,et al.  Tumor heterogeneity and drug resistance. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Mircea D. Farcas,et al.  About Bernstein polynomials , 2008 .

[36]  J. Salk Clonal evolution in cancer , 2010 .

[37]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[38]  R. Iyengar,et al.  Modeling cell signaling networks. , 2004, Biology of the cell.

[39]  Josef Hofbauer,et al.  Evolutionary Games and Population Dynamics , 1998 .

[40]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[41]  P. Maini,et al.  Mathematical oncology: Cancer summed up , 2003, Nature.

[42]  David Basanta,et al.  The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view , 2011, Physical biology.

[43]  K. Pienta,et al.  Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.